Evidence map›Paper›PMID 41539020›Full record

ReviewCurrent opinion in microbiology2026

Insights into the lifecycle of Cryptosporidium and compounds targeting developmental stages.

Zoë Reynolds, Sumiti Vinayak

Abstract readReview
In one paragraph

Review in Current opinion in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zoë ReynoldsDepartment of Pathobiology, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61802, USA.
Sumiti VinayakDepartment of Pathobiology, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61802, USA. Electronic address: sumiti@illinois.edu.

Funding

Molecular signaling mechanisms controlling Cryptosporidium proliferation and developmentR01AI150961 · NIAID · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI ALAM, SUMITI VINAYAK · 2021 to 2025
$1.9M
NIAID NIH HHS R01 AI150961
6 · The paper itself

Abstract

The intestinal protozoan parasite, Cryptosporidium, is a leading cause of diarrhea-associated illness and death in young children, immunocompromised individuals, and neonatal ruminant animals. This apicomplexan parasite completes its entire lifecycle within a single host, involving a timely and coordinated progression through asexual and sexual developmental stages. With no fully effective drugs or vaccines available, a deeper understanding of the parasite's lifecycle stages is crucial for identifying new molecular targets for disease intervention. In this review, we discuss recent advances in understanding the Cryptosporidium developmental lifecycle, stage-specific gene expression, and the role of parasite proteins in invasion, asexual proliferation, and sexual stages. We also discuss the lifecycle stages targeted by a few highly effective anticryptosporidial compounds.

Indexed as

Antiprotozoal AgentsCryptosporidiosisCryptosporidiumLife Cycle StagesAnimalsHumansProtozoan ProteinsAntiprotozoal AgentsProtozoan Proteins

Identifiers

PMID41539020
PMCPMC13007382

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.